Eli Lilly’s Experimental Obesity Pill Shows Promise in Phase 3 Trial Summary Eli Lilly’s experimental obesity pill, orforglipron, has shown potential as a weight maintenance treatment in a Phase 3
Sanofi MS drug hits two setbacks Summary Sanofi’s experimental drug, tolebrutinib, has failed to meet its main goal in a late-stage trial for primary progressive multiple sclerosis (MS). The company
Sobi Snaps Up Gout Drug in $950M Deal for Startup Arthrosi Summary Swedish pharmaceutical company Sobi has acquired Arthrosi Therapeutics, a biotechnology startup developing a potential treatment for gout, in
Lilly’s Retatrutide Shows Promising Results in Phase 3 Obesity Study Summary: Lilly’s experimental obesity drug, Retatrutide, has shown impressive results in a Phase 3 study, with patients on the highest
Pfizer’s Latest Move in the Obesity Market: A $150 Million Deal with Chinese Drugmaker YaoPharma Summary Pfizer has announced a $150 million deal with Chinese drugmaker YaoPharma for the rights
Summary Mirum Pharmaceuticals has announced its acquisition of biotech startup Bluejay Therapeutics, which is developing a treatment for hepatitis D. The deal is worth up to $820 million, with $250
Summary The highly anticipated arrival of hemophilia gene therapies has not lived up to expectations. One therapy has been pulled from the market while two others face challenges in obtaining
Summary: Pharvaris’ pill for hereditary angioedema (HAE) showed promising results in a Phase 3 trial, with a median time to symptom relief of 1.28 hours, significantly faster than a placebo.
Why CVRs Are Becoming the Quiet Engine Behind Today’s Biotech Deals The biotech sector is navigating one of the most complex market environments in recent memory. Volatile valuations, cautious capital,
Summary The U.S. and U.K. have reached a trade deal that will exempt drugs imported from the U.K. from tariffs for three years in exchange for pricing concessions. This agreement